Examining research, development investments with treatment costs for new drugs

JAMA Network

About The Study: In this cross-sectional study of 60 new therapeutic agents approved by the Food and Drug Administration from 2009 to 2018, there was no association between estimated research and development investments and treatment costs based on list prices at the launch of the product or based on net prices a year after launch. Findings of this study suggest drug companies should make further data available if they want to use this argument to justify high prices.

Authors: Olivier J. Wouters, Ph.D., of the London School of Economics and Political Science, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2022.18623)

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.